[Spironolactone in dermatological treatment. On and off label indications].

Abstract

There are no currently FDA/EMEA-approved dermatologic indications for spironolactone and its off-label uses are, among others, female acne, female pattern hair loss, hidradenitis suppurativa or hirsutism. The rationale behind these relays on the mechanism of action of spironolactone which interferes with the hormone-controlled sebum and sweat gland secretion and with androgen stimulated hair growth. The average dose used by the dermatologits is 50-100 mg daily. It should not be used in pregnant and lactating women and it is not used in men due to the risk of feminization. Although further studies to assess its efficacy and safety are necessary, currently spironolactone is regarded as a useful tool in the dermatologic treatment armamentarium.

• Authors: C M Salavastru, K Fritz, G S Tiplica
• Journal: Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete (Hautarzt) Vol. 64 Issue 10 Pg. 762-7 (Oct 2013) ISSN: 1432-1173 [Electronic] Germany
• Vernacular Title: Spironolacton in dermatologischen Behandlungen. "On-label-" und Off-label-Indikationen.
• PMID: 24150826 (Publication Type: English Abstract, Journal Article)

Chemical References

• Dermatologic Agents
• Spironolactone

Topics

• Chronic Disease
• Dermatologic Agents (administration & dosage, adverse effects)
• Dose-Response Relationship, Drug
• Drug-Related Side Effects and Adverse Reactions (etiology, prevention & control)
• Evidence-Based Medicine
• Female
• Humans
• Off-Label Use
• Skin Diseases (drug therapy)
• Spironolactone (administration & dosage, adverse effects)
• Treatment Outcome
• Women's Health